AACR Round-Up: Zentalis, Pieris, Hookipa And Eli Lilly
DNA Damage Response Inhibitors, Fusion Proteins And KRAS Inhibitors
Zentalis outlines promising antitumor activity associated with its WEE1 inhibitor, Phase II trials are planned for Pieris Pharmaceuticals’ fusion protein in HER2-positive cancers, while HPV-positive cancers are being targeted by Hookipa’s immunotherapeutics in arenavirus vectors, and Eli Lilly is planning early-stage clinical trials with its next-generation KRAS inhibitor.
